Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奧賽圖(北京)醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

POLL RESULTS OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING HELD ON JUNE 25, 2026

References are made to the notice (the "**Notice**") and the circular (the "**Circular**") of the 2026 second extraordinary meeting ("**EGM**") of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the "**Company**"), both dated June 4, 2026. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Notice and the Circular.

The Board hereby announces that the EGM was held with the combination of a physical meeting at the conference room of 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, PRC and a virtual meeting online on Thursday, June 25, 2026 at 2:00 p.m. (Hong Kong Time). The EGM was held in accordance with the requirements of the PRC Company Law and the Articles of Association.

As at the date of the EGM, the total number of issued Shares of the Company was 446,898,420 (excluding treasury shares, if any), including 110,781,920 H Shares and 336,116,500 A Shares, all of which entitled the Shareholders to attend the EGM and vote for or against or abstain from voting on the resolutions (the "**Resolutions**") proposed at the EGM. The Company did not hold treasury shares and no voting rights of treasury shares have been exercised at the EGM. The trustees of the share award scheme of the Company holds an aggregate of 3,280,732 unvested Shares (comprising (i) the underlying Shares of the granted share awards which remain unvested; and (ii) such other Shares held for future grant of share awards) with voting rights attached (representing approximately 0.73% of the number of the issued Shares) had abstained from voting on any of the Resolutions at the EGM. To the best knowledge, information and belief of the Company, save as disclosed above, (1) there were no Shares entitling the holder to attend and abstain from voting in favor of the Resolutions proposed at the EGM as set out in Rule 13.40 of the Listing Rules; (2) no Shareholder was required under the Listing Rules to abstain from voting on the Resolutions proposed at the EGM; and (3) no party has stated any intention in the Circular to vote against or to abstain from voting on the Resolutions proposed at the EGM. The Resolutions were put to vote by way of poll.

A total of 286 Shareholders and their proxies holding an aggregate of 301,190,627 voting Shares, representing approximately 67.4% of the total number of voting Shares, attended the EGM. Dr. Shen Yuelei, the chairman of the Company, acted as the chairman of the EGM and presided over it. All the Directors, the senior management of the Company, as well as the secretary of the Board were present at the meeting either in person or by means of telecommunication.

Tricor Investor Services Limited, the Company's H share registrar, two representatives from the Company's Shareholders and a lawyer from Zhong Lun Law Firm, were responsible for vote counting and acted as the scrutineer thereof. The poll results in respect of the Resolutions proposed at the EGM were as follows:

Ordinary Resolution		**Number of Votes (%)**		
		For	**Against**	**Abstain**
1.	To consider and approve the proposed formulation of Remuneration Management System for Directors and Senior Management.	301,186,744 (99.9987%)	1,000 (0.0003%)	2,883 (0.0010%)
Special Resolutions		**Number of Votes (%)**		
		For	**Against**	**Abstain**
2.	To consider and approve the proposed granting of the general mandate to the Board to repurchase H Shares.	301,186,524 (99.9986%)	0 (0.0000%)	4,103 (0.0014%)
3.	To consider and approve the proposed granting of the general mandate to the Board to issue H Shares.	299,018,788 (99.2789%)	2,168,956 (0.7201%)	2,883 (0.0010%)
4.	To consider and approve the proposed application for comprehensive credit facilities and provision of guarantee for the Company and subsidiaries.	299,303,059 (99.3733%)	1,884,685 (0.6257%)	2,883 (0.0010%)

As more than half of votes were casted in favour of the above ordinary Resolution numbered 1, and more than two-thirds of votes were casted in favour of each of the above special Resolutions numbered 2 to 4, all of the above Resolutions were duly passed at the EGM.

WITNESS BY LAWYERS

Zhong Lun Law Firm, the Company's PRC legal adviser, considers that the convening and holding procedures of the EGM complied with the relevant requirements of the PRC Company Law, the Rules for General Meetings of Listed Companies and other laws, regulations and normative documents and the Articles of Association. The qualifications of the attendees, the convener of the meeting, the voting procedures and voting results of the meeting were lawful and valid.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, June 25, 2026

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian as executive Director; Dr. Zhou Kexiang, Ms. Zhang Leidi and Dr. Liu Hongkang as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors; and Ms. Li Yan as employee Director.